AUS
NZ
UK
CA
USA
IND
Highlights:
-
Summit Therapeutics has completed enrollment for the HARMONi Phase III clinical trial, evaluating ivonescimab in combination with platinum-doublet chemotherapy for EGFR-mutated non-small cell lung cancer (NSCLC) patients.
-
The FDA has granted Fast Track designation for ivonescimab, potentially accelerating its development and review process.
-
Topline data from the HARMONi trial is anticipated to be available in mid-2025, including insights from the previously conducted HARMONi-A trial.
Summit Therapeutics {NASDAQ:SMMT} has announced the successful completion of enrollment for its HARMONi Phase III clinical trial. This pivotal study is designed to evaluate the efficacy of ivonescimab, a novel therapeutic agent, in combination with platinum-doublet chemotherapy in patients diagnosed with EGFR-mutated non-small cell lung cancer (NSCLC) who have shown disease progression following treatment with third-generation EGFR tyrosine kinase inhibitors (TKIs). The trial has recruited participants from various regions, including North America, Europe, and China, showcasing the global interest in this promising treatment option.
In a significant development, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ivonescimab in this indication. This designation is intended to facilitate a more rapid development and review process, which may allow for earlier access to the therapy for patients with this aggressive form of lung cancer.
The HARMONi trial is designed with dual primary endpoints focusing on progression-free survival and overall survival. Topline data from the study is expected to be available in mid-2025, providing critical insights into the treatment's effectiveness. Additionally, the analysis will incorporate data from the HARMONi-A trial, which has already led to marketing authorization for ivonescimab in China as of May 24, 2024.
By integrating findings from both trials, Summit Therapeutics aims to gather comprehensive evidence supporting the use of ivonescimab in a patient population with limited therapeutic options. The completion of enrollment for the HARMONi trial marks a crucial milestone in the ongoing efforts to advance innovative treatments for NSCLC, reinforcing Summit Therapeutics' commitment to addressing unmet medical needs in oncology and enhancing patient outcomes.
